Good day and thank you for standing by. Welcome to the EyePoint Third Quarter 2021 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation there will a question-and-answer session. . Please be advised that today’s conference is being recorded. . I would now like to hand the conference over to your speaker today, George Elston, Chief Financial Officer. Please go ahead.

Thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' Third Quarter 2021 Financial Results and Recent Corporate Developments. With me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; and Scott Jones, Chief Commercial Officer. Nancy will begin with a review of recent corporate updates; Dr. Duker will then discuss pipeline developments for EYP-1901, and Scott will comment on recent progress made on our commercial activities. I will close with commentary on the third quarter 2021 financial results. We will then open up the call for your questions. Earlier this morning, we issued a press release, detailing our financial results as well as commercial and operational developments. A copy of the release can be found in the Investor Relations tab on the company website www.eyepointpharma.com. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements as a result of the various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is filed and on file with the SEC, and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. I'll now turn the call over to Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

Thank you George. Good morning everyone and thank you for joining us. We are pleased with our progress during the third quarter as EyePoint Pharmaceuticals continue to make progress across our ocular pipeline to treat serious ocular diseases as well as maintaining customer demand across our commercial business. We remain laser focused on executing on our overarching mission of bringing innovation to patients with serious ophthalmic diseases. Prior to turning the call over to my colleagues I would like to discuss a few of our recent achievements from this past quarter. Importantly our team continues to advance our Phase 1 DAVIO trial for lead pipeline assets EYP-1901, a potential twice yearly treatment for wet age related macular degeneration or wet AMD and we are very much on track to report interim data in the coming weeks. To reiterate our progress throughout 2021 we initiated our Phase 1 trial, dosed the first patient, and completed trial enrollment. Notably last month we were pleased to report preliminary three months safety data for all doses from the DAVIO trial at the American Society of Retinal Specialist citing no serious adverse events, ocular or systemic, no adverse events related significant ocular inflammation or best corrected visual acuity reduction, nor an elevation of intraocular pressure in all 17 patients enrolled. Additionally, no events of endophthalmitis, retinal detachment, or migration into the anterior chamber were reported. We're incredibly excited about our progress and we're looking forward to reporting interim safety and efficacy results later this month. Should the results of our DAVIO interim data prove to be positive, we anticipate starting Phase 2 trials next year. In addition to our focus on EYP-1901, we remain committed to the initiation of a Phase 3 trial for YUTIQ 50 in the fourth quarter of this year. YUTIQ 50…

Thank you Nancy and good morning everyone. Before I begin I would like to sincerely thank Nancy and the entire EyePoint Pharmaceuticals organization for their continued trust in me and overarching support as I begin my new role as Chief Operating Officer. I look forward to building EyePoint into an even more successful clinical and commercial company as we continuously build out our pipeline and grow our business. As Nancy stated earlier, we are excited with the progress thus far on our Phase 1 DAVIO trial for our lead asset EYP-1901, a potential twice yearly treatment for wet age related macular degeneration. We continue to underscore the pride we feel for our clinical and regulatory teams who have so far flawlessly executed our Phase 1 trial. Our team managed to initiate then complete enrollment of all 17 patients in under four months. We're pleased with the recent, very encouraging positive three-month safety data report, and we are looking forward to reporting further safety and initial efficacy data later this month on Saturday, November 13th at the American Academy of Ophthalmology in New Orleans. Wet AMD is a chronic, progressive, and potentially devastating eye disorder. It's hallmark is the development of abnormal blood vessels under the macula which is the center of the retina that leak fluid and blood. It typically presents with blurred and distorted vision and can result in a permanent blind spot in the central vision. It is the leading cause of vision in people over 65 years of age in the United States and other developed countries. Despite safe and effective FDA approved medications on the market to treat wet AMD, there is a significant opportunity for longer lasting therapies than those currently available. EyePoint seeks to provide a reliable, safe, long-term sustained release treatment option that…

Thank you Jay. We're pleased that our core customer demands sustained its rise from pre-COVID levels and we reported 49% increase in net product revenues for commercial products DEXYCU and YUTIQ compared to Q3 2020. Like many commercial companies our net product sales and underlying customer demand were negatively impacted by the COVID-19 pandemic in 2020 and into 2021 and we are pleased to see patients return to doctor’s office and schedule their previously delayed surgeries and procedures. Our Q3 net product revenues of 8.6 million increased from 5.8 million in Q3 2020. This includes net product revenues of 4.7 million and 3.9 million for DEXYCU and YUTIQ respectively. Customer demand was approximately 13,100 units of DEXYCU and 560 units for YUTIQ, increases of 175% and 22% respectively from Q2 2021. Customer demand for DEXYCU continues to stem from both our strong sales and marketing team and our collaboration with our commercial alliance partner and from SRX . Customer demand for YUTIQ remained strong in part a result of the improved our commercial team rolled out this year providing a more optimal procedural experience for physicians and patients. We're incredibly pleased by the progress we have made during the third quarter to return DEXYCU and YUTIQ to pre-pandemic levels. EyePoint’s mission is to provide an unique sustained delivery system across all of our products that require fewer visits to the doctor's office, the key attribute for each product's value proposition that both patients and doctors rely on. We would also like to thank all of our patients and doctors for their continued support in the use of our products. We look forward to updating you on revenues and demand in the quarters to come, I would now like to turn the call over to George to review the financials. George.

Thank you, Scott. As the financial results for the three months ended September 30, 2021 were included in the press release issued this morning, my comments today will be focused on a high level review for the quarter. For the three-months ended September 30, 2021 total net revenue was 9.1 million compared to 15.7 million for the three-months ended September 30, 2020. This includes net product revenue for the third quarter of 8.6 million compared to net product revenues for the third quarter ended September 30, 2020 of 5.8 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2021 totaled 0.5 million compared to 9.9 million in the corresponding period in 2020. This decrease was driven by one-time milestone payments received in Q3 2020 that did not recur in 2021. Operating expenses for the quarter ended September 30, 2021 total 24.4 million versus 17.7 million in the prior year period. This increase was primarily due to a 4.4 million increase in R&D expense, a 2.1 million increase in sales and marketing expense, and a 0.3 million increase in G&A expense offset by a 0.1 decrease in cost of sales. Non-operating expense net totaled 1.4 million and net loss was 16.7 million or $0.58 per share compared to a net loss of 3.8 million or $0.30 per share for the prior year period. Cash and cash equivalents at September 30, 2021 totaled 119.7 million compared to 44.9 million at December 31, 2020. We expect the cash on hand at September 30, 2021 and expected net cash inflows from our product sales will enable us to fund our current and planned operations through the end of 2022. In conclusion we are thrilled that EyePoint’s progress in the third quarter and first nine months of 2021 are well capitalized to advance our product pipeline to keep value inflection points. Thank you all very much for listening this morning and I now turn the call over to the operator for questions.

. Our first question comes from the line of Ken Cacciatore from Cowen and Company. Your line is now open.

Hi everyone, this is Gregory on for Ken. Thank you so much for taking our questions and congratulations on all the progress. So maybe we can talk to Dr. Duker, given the highly anticipated readout next week for DAVIO, could you maybe frame what are the most important aspects of the results investors should focus on given that it will be the first time we'll be seeing data from 1901? And then I have a few more follow-ups.

Sure. Thank you very much for the question. And given that this is a Phase 1 trial, whose primary endpoint is safety, that is the most important thing to focus on, is does the product appear to be safe in the 17 patients. Remember also, we hope to enter a market that has several FDA approved products that are very safe and therefore safety really is paramount. Beyond safety, I think we'd all hope to see some sign that the EYP-1901 insert is controlling with macular degeneration. So given that this is a previously treated population of patients, we would anticipate that if there is some sign of efficacy, it would mean stable visual acuity and stable fluid on OCT. Beyond that, we do hope to show a significant number of patients who are able to go at least four months without having a standard of care rescue. And we'd also hope that there is some reduction in what we would refer to as treatment burden. Treatment burden means calculation of the ratio of how many injections did the patients get prior to enrolling in our study against how many did they get for the six months following enrollment. So I think those five issues with safety being by far the most important are what we all should look closely at.

Thank you. This is very helpful. And then maybe could you also remind us of the number of patients and doses for the four cohorts we'll be seeing data from and how long a follow-up should we expect for the higher dose groups?

Sure. So we have 17 patients enrolled, three patients were enrolled in the lowest dose which was 400 micrograms, one patient was enrolled in a low medium dose which was approximately 1 milligram, eight patients received approximately 2 milligrams, and five patients were in the high dose which is approximately 3 milligrams. We should have virtually all the six-month visits occur prior to data. Again, we have them scheduled for prior to the AAO but given that the patients don't necessarily all come in for their visits when they're scheduled, we certainly can't guarantee that. But the vast majority, well over 90% of the visits should have occurred by the time we release the data.

Yeah, so let me take that. Let me just add a -- which is that we're going to be looking at how far we can get patients out, obviously, at four months, five months, six months and beyond. So I just want to add that it's not just four months.

Yeah. Got it. Thank you so much. And we're looking forward to seeing the data.

Thank you.

Thank you. Our next question comes from the line of Jennifer Kim from Cantor Fitzgerald. Your line is now open.

Hey, good morning. Congrats everyone and thanks for taking my questions. I have a couple here. The first one is just on the quarterly numbers, the implied ASPs was to be a bit lower for YUTIQ index just looking at the number of units sold compared to the revenue performance. And in particular, the DEXYCU units I think were up around 20%, quarter-over-quarter but sales were up around 2%. So I'm just wondering if you have any color here and how we should think about I guess the sales price per product going forward? And then my second question is SG&A and R&D both ticked up a bit this quarter and do you have any color on what drove that and how we should think about modeling those going forward? I have one more but I will wait until after.

George, why don’t you take those.

Sure. Yes, Jennifer a couple of things first with revenue. Keep in mind that the units that we report and the earnings release is underlying customer demand. We recognize revenue based upon purchases by distributors from us and then we report the demand to show the underlying business. And so there's always going to be a disconnect between what we show in customer demand and what actually gets purchased by distributors. And so that is straight, it's not perfect, there's always inventory swings in between. So doing a straight calculation on ASP, isn't really that easy based on those numbers. I will say that product mix does come into play a little bit. YUTIQ has a much higher price than DEXYCU and so I think from a general perspective, our YUTIQ pricing has stayed pretty consistent. That product is not discounted, DEXYCU does go through some level of rebates and discounting for that customer base. And so we're going to see a swing in ASP on a total calculation simply because of the way that unfolds. And I would say that DEXYCU will certainly weigh any swings in that more than YUTIQ will. On the P&L side, R&D is up really driven based upon the ongoing Phase 1 study as we continue to focus on building our pipeline. And so certainly, clinical costs associated with EYP-1901 are a big component of that. There's also some underlying non cash spending related to stock compensation and that's affected both R&D and G&A, as we've continued to build out the R&D organization. That's the quick answer there.

Okay, great. And then one more question. Jay, first of all congrats again on your new role. For you I'm just wondering, what are you most excited to do under your new role, where are your priorities, and I guess what would you highlight in terms of where your focus is?

Well, thanks for the congratulations. It's my third day on the job so I am just trying to find out where the coffee maker is. But, my priorities at a high level are kind of doing what I've been doing for 30-31 years, which is helping people to see better. This is just a different way of doing it. We are focusing on a large population, not an individual sitting in front of me in my office. So I think with success, this type of position we're able to really help people in a very, very large fashion as opposed to one at a time. This skill set that I bring, I think I've honed for the last 30 years running a large department and starting companies and in having responsibilities of moving programs forward. I think that I am still going to have a lot to learn, because there's a lot about the corporate side of things that despite having been a part of the company for almost a year and a half, I've still got to really get a handle on. But essentially, at a very high level what I'm trying to do is save peoples sight.

Great, and are you more excited, I guess in terms of where your excitement is, is it on 1901 or is it really on driving I guess, the technology and given your previous experience with Hemera early pipeline?

Yeah, it's even beyond that. Yeah, I mean, those are all things that are exciting. The Durasert technology is really terrific in taking a step back and looking at it from the outside and having seen it for -- and used for almost 30 years, I think it's a highly underutilized asset. I think there's a lot more that we can do with it. But it goes beyond Durasert because we are committed to being the leader in drug delivery in the eye. And so we are evaluating other potential drug delivery systems. But in the end, those are all tools to achieve better vision, better life, easier times for patients, families, and frankly for insurers as well. I mean, we have a whole constituency that we're trying to help here. So the delivery system or tools EYP-1901 is the first step. If we can show that a small molecule like can be safely and successfully delivered to the eye, I think there's a wealth of other similar type of molecules, or other mechanism of action that we can potentially deliver. But at a high level and a personal level I like challenges and I like to take on things and be successful with them. So I don't think that taking just a single program or single molecule, or a single delivery system is what excites me. It's moving the company forward with a common goal.

Awesome, great. Congrats again. And thanks everyone.

Thank you. Our next question comes from Yatin Suneja from Guggenheim. Your line is open.

Hey guys. Thank you for taking my questions. And Jay congrats from my side as well. Just a couple from me, so at AAO we're going to get the five-month data for the high dose, would you release six-month data for all doses once it is available, let's say in December or do we have to wait for a scientific conference for a full six-month data release?

Yeah, I'll take that question. So we were always just a bit cautious in what we wanted to commit to in terms of what we would show at AAO because you never know if patients will make their business in a timely way. The good news is they have and so what we expect to show at AAO is all cohorts, well, let me back up, we're going to show the low dose, the low mid dose, and the mid dose, all the way through six months for safety and efficacy. And then in the high dose, we will show all patients, there's one patient who has not yet come into their visit, if we can get that patient in before AAO we will show that patient otherwise we will be shy of one patient and we will show the four out of five patients through six months in a high dose cohort with one patient at five months. So basically, we're going to be able to show almost all the data through six months, excuse me, up to six months, let me be clear, up to six months, and then perhaps one patient will be still at five months in the high dose cohorts.

Got it. Very good, very helpful, then couple more. So obviously, the drug seems to be very, very safe and one of the questions that I have gotten from investor is that what is your view on the dose level, is it -- are these -- the fact that we are seeing such a good safety profile could that be a function of the dual under dosing patient or do you think these doses are relatively active and you should be able to reach the therapeutic window that you are hoping with one of these three things scheduled that you have?

Yeah, let me comment real quickly and then I'm going to turn it over to Jay. So first of all, we're not going to give any forward guidance on what we expect to see. So I want to be very clear about that. And of course there's always in any therapeutic area, you always have that trade-off between safety and efficacy. But with that being said, as you know, we have a very remarkably good safety profile and frankly, I think you'll just have to wait and see what the data shows when we roll it out at AAO. Jay, I'm going to let you expand on that if you have anything else you'd like to add.

Not a lot, except to state that in our preclinical models, in our IND enabling studies, there was a very good safety profile for both vorolanib and EYP-1901, vorolanib and Durasert. And we never found the maximally tolerated dose in animals. And so that I will agree with Nancy that we will have some efficacy data to share in another week and a half or so. And we'll leave it at that.

Got it, just one final question, if I may. So with regard to the, I think Jay you spoke about it today, but I joined a little bit later, so with regard to the changes in -- and OCT I think you mentioned about five plus or minus would be okay and 50 microns would be okay. Just trying to get a sense of how likely a letter or an OCT loss would be, I'm not sure if that five letter positive would be fine but a drop, I don't know how that, we should be thinking about that?

So I think you need to think about it in a couple of ways. There's really three kind of views of this and the first view is what does the FDA think because ultimately we need to get the product FDA approved. So the FDA -- if the FDA says that -- and again, this is I pick a number it doesn't matter 2,3,4,7,10 letters is an approvable endpoint even for a loss, and then the FDA has spoken. The second thing is what do the retina specialist feel, what is an acceptable safety profile and efficacy profile to use the product. Now remember, we report data across a large population or certainly the Phase 1, I wouldn't call it a large population, it's an equal 17. It's a small population. But that doesn't mean that you can't pick out even if in a large population, the efficacy doesn't look strong but in individual subgroups it does and you can identify those subgroups, then you can have a very successful product by choosing the patients you use it on well. And that's no different than any other drug product. What's different in this area is we didn't have an option before, it was an injectable anti-VEGF, LUCENTIS, EYLEA, Avastin and if you inject the monthly, they all work about the same, and they're all about the same safety. So this is a paradigm shift now, because what we hope to accomplish is true sustained release for many months, and not just a month or two. And it doesn't need to work perfectly at every patient as long as it's safe and one can identify the groups of patients that it does work well in. And so the last group that needs to be satisfied, of course, is the patients. They…

No, that was very good. Thank you so much.

Thank you. Our next question comes from the line of Yale Jen from Laidlaw and Company. Your line is now open.

Good morning and thanks for taking the questions and congrats on the progress. In terms -- my first question in terms of the 1901, you have 3 milligrams and 2 milligrams of groups and also you will highlight some of the efficacy information sort of categories that need to be paid attention to. Do you anticipate most of the efficacy or signals or signs of efficacy will likely be in those high dose groups or you may even think that even at 1 milligrams, you could start to see some sort of directional changes.

We can't speculate. There really is no kind of guidance we can give here about efficacy for any of the groups.

Okay, that's fine. I appreciate that. And then maybe just one more question in terms of YUTIQ Calm, I think that was very useful information. Is there any follow-up in terms of reporting or what should we anticipate maybe sometime in 2022, additional sort of update from that?

Yeah, we expect to give continuous updates on that data set that's going to go out for a minimum of five years and possibly even be off. So as I said in the press release, it's really an incredible amount of data that we're going to be able to capture on the longitudinal etiology of the progression of the disease, which no one has right now. So we feel like we're contributing not only to the overall understanding of posterior segment uveitis, but then also YUTIQ helps to manage that disease. So we expect that we'll be giving regular consistent updates on that longitudinal study as it progresses.

Okay, great. And maybe one final question here is in terms of YUTIQ, six months for trial to start in this quarter. What should we anticipate be the primary endpoint for that study? And thanks.

It's going to be run identical to our Phase 3 programs for the YUTIQ three-year program. So it will be reduction in uveitic flares. Obviously, you always are going to be looking at other secondary endpoints, obviously, safety of course. But -- and obviously some vision maintenance or how you control the vision as these patients progress with their disease, but the primary endpoint will be reduction in uveitic flares.

Okay, great. Thanks a lot and congrats and we look forward the datas.

Thank you.

Thank you. Our next question comes from the line of Yi Chen from H.C. Wainwright. Your line is open.

Thank you for taking my questions. Could you comment on the volume of ocular surgery in the current quarter whether it has returned to the normal volume compared to pre-COVID times?

I can’t, Jay you want to answer that? Can you repeat that, that question was a little hard to understand.

I wonder if you can comment on whether the volume of ocular surgeries have returned to the normal levels?

Yeah, I think the answer is probably not. But I'm not sure that there's any central place one could look for that data this soon. You can look at claims data but that usually takes a while to find. So I'm just off the cutting it here, talking to my colleagues and knowing what's going on, at least in the New England area and outside. I think the volumes are close to pre-COVID in the 90% but not quite there. But again, that is non-scientific.

Scott, do you want to comment on that as our Head of Sales and what you're seeing with the field is seeing out in the real world as well.

Absolutely. Thanks, Nancy. Specifically, to cataract surgery, rather than focusing on all ophthalmic surgeries, what we're seeing in the cataract market, it is slowly returning back to normal. We are seeing certain areas that will pop up and specifically related to COVID having an outbreak in particular areas where we see a slowdown. So while I can't give you a specific number of cataracts that occurred during the second or third quarter, we are seeing most areas of the country slowly return back to normal levels.

Thank you. My next question is FDA recently approved Susvimo or the poor delivery system with Ranibizumab for the treatment of wet AMD for up to six months, so what does 1901 need to demonstrate to outcompete Susvimo on the market in the future.

Jay, why don’t you take that.

So a couple of things. First of all, from a safety issue. We all need to be aware that to place this implant there's surgery involved and there's always some risk to this surgical operation. The second thing is starting even in the Phase 1 where one out of 20 patients in their Phase 1 trial got endophthalmitis which is a serious infection of the inside of the eye. 1.5% of the patients approximately in the Phase 3 trials got endophthalmitis and so that is something we are -- we hope that in office injectable could do better from a safety perspective, and certainly back to the surgical part of it. We think that from a convenience perspective, not having to go to the operating room in relatively elderly patients is going to be an advantage as well. Remember, also our drug is different, the mechanism of action is different. And so that there may be some efficacy around receptor blockage and being able to block all isoforms of VEGF that we may see as further studies are performed. So that, congratulations to the company that was a tough slog to get that through. It's a really game changer, and potential paradigm shift. But we believe that if our product can show safety in similar efficacy, that because we're non-surgical, and because we're likely to have fewer cases of endophthalmitis, that we will be able to carve our market share.

Got it, thank you.

Thank you. At this time, I'm showing no further questions. I would like to turn the call back over to Nancy Lurker, CEO for closing remarks.

Thank you everyone for joining today. And we very much look forward to giving you an update at -- post our AAO data release. Thank you again.

This concludes today's conference call. Thank you for participating, you may now disconnect.